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Objective: To investigate the changes in plasma lipids and lipoproteins, low-density lipopro­
tein (LDL) oxidizability, and plasma homocysteine during postmenopausal sequential 3-monthly 
hormone replacement therapy.
Design: Open longitudinal prospective study.
Setting: Gynecological outpatient department of a university hospital.
Patient(s): Thirty-nine healthy nonhysterectomized postmenopausal women.
Intervention (s): Oral conjugated estrogen, 0.625 mg/d, combined with oral medrogestone 
10 mg/d during the last 14 days of each 84-day treatm ent cycle, The treatment was given for 
four treatm ent cycles of 84 days (1 year).
Main Outcome Measure(s): Plasma lipids and lipoproteins, LDL oxidizability, and plasma 
homocysteine.
Res uit (s): After 1 year of treatm ent plasma concentrations of total cholesterol and LDL 
cholesterol were 3.5% and 8.7% lower, respectively. High density lipoprotein cholesterol, apolipo- 
protein A-I, and triglycerides were 6.5%, 9.0% and 16% higher, respectively. Apolipoprotein B 
concentration remained unchanged. The results on LDL oxidizability were inconsistent. Plasma 
homocysteine decreased with 12.3% during the first 6 months of treatment in women with 
higher homocysteine concentrations at baseline. These values returned to baseline levels during 
the second half year of treatment.
Conclusion(s): This sequential hormone regimen induced beneficial changes in the conven­
tional lipid and lipoprotein risk estimators, whereas the observed changes in the other markers 
remained inconclusive and/or of minor importance. Fértil Steril® 1997;67:67-73
Key Words: Postmenopause, estrogen, progestogen, lipids, lipoproteins, LDL oxidizability, 
homocysteine
Hormone replacement therapy (HRT) is known to 
reduce vasomotor symptoms, genital atrophy, and 
several atypical complaints (e.g., sleeplessness, tired­
ness, painful joints, and depressive mood changes)
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in postmenopausal women (1, 2). Furthermore, it 
has been reported to reduce the incidence of osteopo­
rotic fractures (2) and of cardiovascular disease (2, 
3). To accomplish the latter two preventive effects of 
HRT, long-term supplementation is recommended in 
selected groups of subjects at increased risk (2),
To prevent the development of endometrial hyper­
plasia and carcinoma in nonhysterectomized women 
the addition of progestogen to the estrogen adminis­
tration is recommended (4). A disadvantage of se­
quential estrogen-progestogen therapy, however, is 
that it restores vaginal bleeding, which is an im­
portant reason for poor compliance in many women 
(5). Therefore, alternative treatment regimens, such 
as continuous combined estrogen/progestogen regi­
men and 3-monthly progestogen administration dur­
ing estrogen supplementation (6, 7), currently are
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being investigated to reduce the frequency and se­
verity of the bleeding episodes, thereby improving 
patient compliance.
Until now, cardiovascular consequences of such 
alternative hormone therapies have not been pub­
lished. Reducing the frequency of progestogen ad­
ministration may reduce the reported adverse effect 
of progestogens on the lipid profile (8) and therefore 
be beneficial with respect to the cardiovascular risk. 
However, it may also increase the risk of developing 
endometrial hyperplasia (6, 7). Therefore, this alter­
native HRT regimen needs more research before it 
can be considered for general use.
To approximate the influence of HRT regimen 
with respect to the risk of developing cardiovascular 
disease (CVD) it is common practice to study the 
changes in plasma lipids and lipoproteins, However, 
these changes only partly contribute to the preven­
tive effects of HRT on CVD risk in postmenopausal 
women (9).
New risk estimators of great interest are the size 
of low-density lipoprotein (LDL) particles and their 
susceptibility to oxidation in vitro. It has been re­
ported that small LDL particles (10) as well as oxi­
dized LDL particles (11) have greater atherogenic 
properties than native LDL. Furthermore, small 
LDL particles are more susceptible to oxidation (12). 
For LDL oxidation three parameters are relevant 
(13): [1] the lag time, [2] the oxidation rate, and [3] 
the maximal amount of dienes produced at the end 
of the final oxidation. The lag time is the time needed 
to obtain a significant increase in lipid peroxidation 
products (dienes) and is considered a function of the 
amount of antioxidants present in the LDL. The rate 
at which lipid peroxidation occurs is another rele­
vant parameter of LDL oxidizability. Finally, lipid 
peroxidation stops because of the lack of substrate: 
the total amount of dienes produced is the third rele­
vant parameter of LDL oxidizability. Exogenous hor­
mones may influence LDL oxidizability (14).
Homocysteine has been found to be another im­
portant risk factor for CVD independent of plasma 
lipid profiles (15). Its reported increase after meno­
pause has been suggested to explain part of the in­
creased risk of developing CVD in postmenopausal 
women (16). The recently published data on de­
creased homocysteine levels during HRT (17) may 
indeed partially account for the decreased risk in 
CVD during postmenopausal HRT.
This study was designed to investigate the effects 
of 3-monthly progestogen administration during es­
trogen supplementation as an alternative for the 
usually practiced monthly administration. This arti­
cle reports the effects of this regimen on plasma lip­
ids and lipoproteins, parameters of LDL oxidizabil­
ity, and plasma homocysteine.
Patients
This study was approved by the Institutional Re­
view Board of the University Hospital Nijmegen. 
The participating women were recruited by adver­
tisement in a local newspaper. Selected subjects 
were healthy postmenopausal nonhysterectomized 
women aged 45 to 60 years who gave their written 
informed consent on beforehand. They were amenor- 
rhoic for at least 6 months and their serum FSH 
concentrations were higher than 36 mlU/mL (con­
version factor to SI unit, 1.00). No estrogen or pro­
gestogen therapy was used within 90 days before 
screening. Excluded were women with a history or 
active presence of any contraindication for HRT. In 
addition, also excluded were women with a systolic 
blood pressure higher than 160 mm Hg and diastolic 
blood pressure higher than 100 mm Hg, an endocrine 
disease except for controlled thyroid disease, and to­
tal cholesterol concentrations higher than 7.5 mmol/ 
L. Women with any malignancy except for succes- 
fully resected basal cell skin cancer, malabsorbtion 
disorders, obesity (exceeding 20% of ideal range for 
weight and height), a smoking habit, alcohol or drug 
abuse, or malignant changes on the prestudy mam­
mogram were not included. Furthermore, use of 
lipid-lowering agents, dopaminergic or antidopamin- 
ergic drugs, niacin, clonidine, and tibolone within 30 
days of the screening was not permitted. None of the 
women reported supplementation of vitamins re­
lated to homocysteine metabolism, such as vitamin 
B6, Bi2 and folate supplements.
Beside medical history, the screening consisted of 
physical and gynecologic examination, including Pa­
panicolaou smear and endometrial biopsy by micro­
curettage (Endocurette; Farina Lanfranco, Venezia, 
Italy), mammography (unless performed within 6 
months before screening), routine laboratory hema­
tology, blood chemistry, and urinalysis determina­
tions. Furthermore, FSH and lipid and lipoproteins 
were assayed. At baseline, i.e., between 7 and 21 
days after screening, the lipid and lipoproteins were 
quantified again to assess possible fluctuations in 
time. Also, plasma samples were taken for homocys­
teine assays and then the study treatment was 
started. Baseline values were used in calculations 
and shown in Tables 1 to 4. On cycle days 82 through
84 of the 84-day cycles two and four, the endometrial 
biopsy was repeated and blood samples were drawn 
for determination of lipids, lipoproteins, and homo­
cysteine. At cycle four the Papanicolaou smear, 
the mammography, routine laboratory hematology, 
blood chemistry, and urinalysis were repeated.
After screening, 41 women were included. One 
woman was considered a screening failure because
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a mammographie lesion suspect for carcinoma was 
detected before study entry. There were three drop­
outs. One woman was excluded in cycle one from 
further study because of bad compliance. Further­
more, two women were excluded in cycle three, one 
subject because of unspecific fatigue and tender 
breasts, and the other because of progressive head­
aches.
All women were treated daily with conjugated es­
trogen (0.625 mg/d, Premarin®; Wyeth Laboratories, 
Hoofddorp, The Netherlands), for four treatment cy­
cles of 84 days and with medrogestone (10 mg/d, 
Colpro®; Wyeth Laboratories) during the last 14 
days of each 84-day treatment cycle.
Blood Sampling
Venous blood was obtained in evacuated collection 
tubes for FSH and blood chemistry (Corvac®, Sher­
wood Medical, St. Louis, MO) after a 12-hour fast. 
A 15% solution of 15.0 mg K 3 -E D T A  (Sherwood Med­
ical, Ballymoney, Northern Ireland) was added to 
blood drawn for analysis of hematologic parameters, 
lipids, lipoproteins, and homocysteine. Plasma was 
isolated or separated within 1 to 2 hours after blood 
sampling. Serum concentrations of FSH were mea­
sured with a specific immunoradiometric assay 
(Medgenix, Fleurus, Belgium).
•7
Lipids and Lipoproteins
Very low-density lipoproteins were isolated from 
plasma within 5 days after blood sampling by ultra­
centrifugation at d = 1.006 g/mL using a Kontron 
TFT 45.6 rotor for 16 hours at 168,000 X  g  at 14°C 
in a Beckman L7-55 ultracentrifuge (Beckman In­
struments, Inc., Palo Alto, CA). High-density lipo­
protein cholesterol (HDL-C) in stored plasma sam­
ples was determined weekly by the polyethylene 
glycol 6000 method. For HDL-C the interassay coef­
ficient of variation (CV) amounted to 2.3% (n = 20). 
Plasma total cholesterol and triglycerides (TG) were 
measured by enzymatic methods using commercially 
available reagents (CHOD-PAP cholesterol reagent, 
cat. no. 237574; Boehringer Mannheim, Mannheim, 
Germany, and SERA-PAK TG cat. no. 6684; Miles, 
Milan, Italy). Both measurements were performed 
with a centrifugal analyzer (Multistat III; Instru­
mentation Laboratory, Lexington, MA). Interassay 
CVs were 1.7% and 1.5%, respectively (n = 20). The 
accuracy check for cholesterol against an Abell-Ken- 
dall method approved by the Centers for Disease 
Control (CDC; Atlanta, GA) was within 3% of target 
values. Low-density lipoprotein cholesterol (LDL-C) 
was calculated by subtracting the cholesterol con­
tent in the d < 1.006 g/mL fraction and in the HDL 
fraction from total plasma cholesterol. Plasma sam­
ples used for apolipoproteins and total homocysteine 
determinations were stored at —80°C until the end 
of the study. To minimize the imprecision all sam­
ples from the same subject were analyzed in dupli­
cate in the same run. Apolipoprotein (Apo) A-I and B 
were measured by immunonephelometry; accuracy 
was adjusted to CDC criteria on the base of an ex­
change of sera.
Low-Density Lipoprotein Isolation and In Vitro
Oxidation
Plasma was separated from the blood within 1 to 
2 hours and aliquots were stored at ~80°C in the 
presence of 6 g saccharose/L. To minimize analytical 
variation, all samples of the same subject were ana­
lyzed in the same run. Low-density lipoproteins were 
isolated by a short-run ultracentrifugation method 
and were thereafter tested for their susceptibility to 
copper-induced LDL oxidation in vitro (18). Briefly, 
after isolation and washing by subsequent ultracen­
trifugation for 16 hours at 168,000 X g , the LDL 
was dialyzed for 24 hours in the dark at 4°C against 
phosphate-buffered saline (pH 7.4), containing 10 
/¿mol/L EDTA. The buffer was made oxygen-free by 
vacuum degassing, followed by purging with nitro­
gen. The LDL-containing sample was filtered 
through a 0.45-//m filter and diluted with dialysis 
buffer to a final concentration of 0.05 mg LDL-pro- 
tein/mL and 10 /imol EDTA/L. The oxidation was 
initiated by the addition of a freshly prepared solu­
tion (15 /¿mol/L) of copper chloride (CuCl2). The ki­
netics of LDL oxidation were determined by monitor­
ing the change in the 234-nm diene absorbtion on 
an UV-spectrophotometer (Lambda 5; Perkin-El- 
mer, Norwalk, CT), equipped with a six-position au­
tomatic sample changer, at 30°C. The change of ab­
sorbance at 234-nm versus time was divided into 
three consecutive phases, i.e., a lag phase, a propa­
gation phase, and a decomposition phase. Oxidation 
parameters (lag time, maximal rate of oxidation, and 
total amount of conjugated dienes formed during oxi­
dation) were calculated as described previously (18).
Fatty Acids in LD L
The LDL samples (0.4 mL) were saponified by in­
cubation with 1.6 mL of 0.3 mol NaOH/L in 90% 
ethanol (vol/vol) at 37°C for 1 hour. To 0.4 mL of the 
mixture, 0.4 mL of water and 50 ¡jL of 12 mol HCl/ 
L was added. The fatty acids were extracted twice 
with 2 mL n-hexane. The pooled organic phase was 
evaporated to dryness under a stream of nitrogen. 
The residue was dissolved in 100 jllL of ethanol 
containing 400 ¡jlmol/L of heptadecanoic acid as an 
internal standard and derivatized to 4-nitrophenyl- 
hydrazides as described elsewhere (19). To the hy-
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drazides mixture 0.2 mL of 0.5 mol/L Tris (pH 10.0) 
and 2 mL of n-hexane was added. After vortexing 
for 30 seconds and centrifugation (1,500 X g  for 5 
minutes) the top n-hexane layer was evaporated un­
der a stream  of nitrogen at room temperature. This 
procedure was repeated twice. The residue was dis­
solved in 800 ¡Új of absolute methanol, and a 2-//L 
aliquot was analyzed for fatty acids by high-perfor­
mance liquid chromatography (HPLC; Spectra Phys­
ics, Eindhoven, The Netherlands). A ChromSep col­
umn packed with Chromspher C8 (20 X 100 mm; 
Chrompack, Middelburg, the Netherlands) was used 
to elute the fatty acids with 80% (vol/vol) acetonitrile 
(pH adjusted to 4.5 with sulfuric acid) at a flow rate 
of 0.25 mL/min. The absorbance at 390 nm was 
measured with a Spectra Physics (SP 8450) spec­
trophotometer (Spectra Physics, Eindhoven, the 
Netherlands). For technical reasons the fatty acid 
measurement in LDL both at baseline and cycle two 
was performed in only 27 women.
Vitamin E
The vitamin E concentrations in LDL were deter­
mined by HPLC as described previously (12), For 
technical reasons the vitamin E measurement both 
at baseline and cycle two was performed in only 19 
women.
Homocysteine
Total homocysteine was measured in plasma, 
stored at -80°C until the end of the study, by HPLC 
followed by fluorimetrie detection according to Fisk- 
erstrand et al. with some modifications (20 ). The de­
tection limit was 0,5 ¿¿mol/L and the intra- and in­
terassay coefficient of variation amounted both to 
<5% .
Statistics
Unless indicated statistical “endpoint analyses” 
were performed on data of 39 women, of whom at 
least data at cycle two were available, using the “last 
visit carried forward” procedure. All statistical com­
parisons were performed with the Friedman two- 
way analysis of variance, and the Wilcoxon’s signed- 
rank test, A P  value < 0.05 was considered to be 
statistically significant. Statistical analyses were 
performed with the Dyna-stat computer program 
(Dynamic Microsystems, Inc., Washington, D.C.).
RESULTS
Study Population
Characteristics of the study population are given 
in Table 1 , During the treatm ent period no clinically
Table 1 Characteristics of the Study Population*
Baseline Cycle 4
Age (y) 52.6 ± 3.5
Amenorrhea (mo) 41.7 ± 32.1
Body mass index (kg/m2) 24.0 ± 2,6 23.7 ± 2.5t
Blood pressure (mm Hg)
Systolic 130 ± 17 130 ± 15
Diastolic 83 ± 9 80 ± 8t
* Values are means ± SD (n = 39; except for cycle 4; n = 38). 
t P < 0  ,05 (Wilcoxon’s signed rank test; comparing cycle 4 with 
baseline).
relevant changes were found in body m ass index and 
blood pressure.
Lipids and (Apo) lip opro teins
Fasting plasma concentrations of lipids and lipo­
proteins a t baseline and on cycle days 82 through 84 
of cycles two and four are given in Table 2. Between 
screening and baseline no significant differences 
were detected in the plasm a lipids and lipoproteins, 
except for a 10,1% difference (P = 0.04) in the triglyc­
erides (screening: 1.19 ± 0.56 mmol/L; baseline: 1,07 
± 0.37 mmol/L). Compared with baseline values, to­
tal cholesterol and LDL-C were 3.5% (P <  0.05) and 
8.7% (P <  0.01) lower, respectively, whereas HDL- 
C and TG were 6.5% (P <  0.05) and 16% (P <  0 ,01 ) 
higher, respectively. Parallel to HDL-C, Apo A-I was 
9.0% (P <  0 .0001) higher, whereas Apo B rem ained 
unchanged. Furtherm ore, the  atherogenic indices
LDL-C/HDL-C and Apo B/Apo A-I were 13% (P
<  0.001) and 11% (P <  0.0001) lower, respectively.
LDL Oxidation
The LDL oxidation characteristics showed minor 
changes after two cycles of trea tm ent (6 months): 
lag time decreased from 109 ± 24 to 105 ± 22 m in­
utes (mean ± SD) (P <  0,05), oxidation ra te  de­
creased from 9.6 ± 1.6 to 9.3 ±  1,7 nmol dienes/min 
per milligram LDL protein (mean ± SD), and the 
maximum amount of produced dienes decreased 
from 552 ± 65 to 530 ± 59 nmol/mg protein (P 
<0.01), Table 3 shows data  of fatty  acid composition 
and vitamin E contents in LDL. The percentages of 
palmitic acid, stearic acid, oleic acid, and linoleic 
acid, and the vitamin E concentration changed sig­
nificantly.
Homocysteine
Fasting plasma homocysteine was 6.7% lower (P
<  0.05) in cycle two, but re tu rned  to baseline level 
in cycle four (Table 4). W hen dividing the study pop­
ulation into women with lower plasm a homocysteine
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Table 2 Plasma Concentrations of Lipids, (Apo)lipoproteins 
and Ratios*
Table 4 Plasma Concentrations of Total Homocysteine*
Baseline Cycle 2 Cycle 4 p l .!
Total cholesterol 5.69 •4- 0.76 5.38 -h Q.77§ 5.49 ■f- 0.80± <0.01
HDL cholesterol 1.53 ± 0.30 1.57 -h 0.30 1.63 - h 0.30$ <0.05
LDL cholesterol 3.80 0.75 3.40 0.7811 3.47 0.85§ <0.01
VLDL cholesterol 0.36 0.20 0.41 0.22 0.39 ± 0.20 <0.05
Triglyceridest 1.07 4 - 0.37 1.30 0.5411 1.24 H- 0,45§ <0.001
VLDL
triglycerides 0.60 H- 0.35 0.64 0.39 0.58 ■4" 0.31 NS
Apolipoproteine A-Î 1511 173 1611 ■4- 20311 1647 -t- 18711 <0.001
Apolipoproteine B 1130 195 1104 ± 216 1106 -W 206 NS
Ratios
LDL-chol/HDL-
chol 2.61 0.74 2.27 + 0.8011 2.25 ± 0.8111 <0.001
Apo B/Apo A-I 0.76 0.17 0.70 ¥lÉH 0.1611 0.68 0.171) <0.001
Baseline Cycle 2 Cycle 4 PI­
Total groupé 13.3 ± 2.5 12.4 ± 2.5H 13.3 ± 3.1 NS
Higher-group§ 15.4 ± 2.0 13.5 ± 2.6** 14.8 ± 2.3 NS
Lower-groupU 11.4 ± 1.0 11.4 ± 2.2 12.0 ± 3.2 NS
* Values are means ± SD; Concentrations in /imol/L. 
t Friedman’s two-way analysis of variance (testing for differ­
ences between baseline, cycle 2 and cycle 4), followed by Wilocox- 
on’s signed rank test (testing for differences versus baseline). NS, 
not significant, 
t Total group: n = 23.
§ Higher group: total homocysteine > 13.3 ¿¿mol/L (n = 11),
II Lower group: total homocysteine < 13.3 /xmol/L (n = 12). 
flP < 0.05.
**P < 0.01.* Values are means ±  SD (n = 39; except for cycle 4; n = 38). Concentra­
tions are expressed in mmol/L (except apolipoproteins in mg/L).
t Friedman’s two-way analysis of variance (testing for differences be­
tween baseline, cycle 2 and cycle 4), followed by Wilcoxon’s signed rank
test (testing for differences versus baseline). NS, not significant. acceptance of, and compliance with, Combined HRT
§p<o.oi. (5). Alternative treatment regimen, as continu-
p < ° 001* ous combined estrogen-progestogen regimen and
3-monthly progestogen administration during es­
trogen supplementation may improve patient com- 
concentration (Lower group: baseline homocysteine pliance by reducing the frequency and severity of
< 13.3 ¿¿mol/L) and women with higher plasma ho­
mocysteine concentration (Higher group: baseline 
homocysteine >13.3 ¿¿mol/L), only the Higher group 
showed significantly lower concentrations in cycle 
two (-12.3 % yP  < 0.01), but no significant difference 
was detected between cycle four and baseline. No 
significant differences were found in the Lower
bleeding. Reduced frequency of progestogen admin­
istration has been reported to offer not only an ac­
ceptable cycle control (6), but also an increased ten­
dency to develop endometrial hyperplasia (6, 7). 
Long-term safety studies with sequential 3-monthly 
estrogen-progestogen combinations are needed to 
investigate the relevancy of such treatment for rou­
tine use.
Until now, cardiovascular consequences of sequen­
tial 3-monthly HRT have not been published. It was 
hypothesized that reduced frequency of progestogen 
In nonhysterectomized women the sequential ad- administration may reduce the reported adverse ef- 
dition of a progestogen to the estrogen replacement feet of progestogens on the lipid profile (8) and there- 
therapy induces vaginal bleeding, which impairs the fore be beneficial with respect to cardiovascular risk.
This 3-monthly HRT regimen was evaluated con­
cerning the changes in several important cardiovas-
group.
DISCUSSION
Table 3 Fatty Acid Composition and Vitamin E Content of 
LDL in Plasma*
Baseline Cycle 2
Palmitic acid (%)
Stearic acid (%)
Oleic acid (%)
Linoleic acid (%)
Arachidonic acid (%)
Vitamin E (//mol/L)
Vitamin E/linoleic acid (nmol//¿mol) 
Vitamin E/PUFA (nmol/¿¿mol) 
Vitamin E/apo B (nmol/mg) 
PUFA/total fatty acids (%)||
21.5
6.3 
18.2
46.6
7.4 
11.8
5.6
4.9
11.6 
55.6
± 1.7
± 0,4 
± 2.2 
± 3.4 
± 1.5 
± 4.4 
± 1.1 
± L0 
± 2.7 
± 2.6
23.9 
5.9
19.2
43.3
7.7 
10.0
5.5
4.7 
10.6
54.9
± 2.5§ 
± 0.4§ 
± 2.5$ 
± 4.6§ 
± 1.6 
± 2.8t 
± 0.7 
± 0,5 
± 1,4 
± 3.9
* Values are mean ± SD (n = 27; except vitamin E and ratios; 
n = 19), Statistics were performed with Wilcoxon’s signed rank 
test (comparing cycle 2 with baseline), 
f P < 0.05.
iP  < 0.01.
§P< 0.001.
Il PUF A, poly unsaturated fatty acids.
cular risk factors. Special interest was given to new 
cardiovascular risk estimators, because there is no 
doubt that lipids and lipoproteins explain only part 
(9) of the cardioprotective influence of HRT (2, 3).
It was shown that most plasma lipids and lipopro­
teins, except for TG, underwent beneficial changes 
with respect to the risk of developing CVD. This 
finding is in concordance with many studies that 
investigated the effects of HRT on plasma lipids and 
lipoproteins. When compared with sequential regi­
men of conjugated estrogen and monthly medroge- 
stone (5 mg/d) (21), the 3-monthly administration 
of medrogestone (10 mg/d) showed more estrogenic 
effects, as is apparent from the increase in HDL- 
C and apo A-I (and TG) and the decrease in total 
cholesterol and LDL-C. It appears therefore that re­
ducing the frequency of progestogen administration 
may benefit the lipid profile and so reduce cardiovas-
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cular risk. This could be of great importance consid­
ering the fact that this alternative HRT regimen was 
designed to improve compliance, especially for those 
women in need of long-term treatment to prevent 
CVD. However, this hypothesis needs further re­
search by prospective randomized studies, because 
minor variations in different studies over time in 
different women do not allow this conclusion to be 
drawn.
Low-density lipoprotein oxidation has been sug­
gested to be an additional important risk factor for 
atherogenesis. Once LDL is infiltrated in the vascu­
lar bed, a supply of antioxidants prevents lipidperox- 
idation of the polyunsaturated fatty acids within the 
LDL. Indeed, 17/3-E2 administered by intra-arterial 
infusion, patch application, or by implantation re­
duced the lag time of the LDL oxidizability curve 
(14, 22). In our study we observed a decrease in the 
lag time of in vitro oxidation with 3.7%, a significant, 
but probably not a physiological difference because 
the ratio of vitamin E per milligram Apo B did not 
change. Furthermore, oxidation rates remained sim­
ilar, despite a slight but statistically significant de­
crease in the relative content of linoleic acid, which 
is sensitive to oxidation in contrast to palmitic acid 
or oleic acid.
Inherent to the choice of hormone regimen, 
changes in plasma lipoproteins as well as in LDL 
oxidizability are small. Previously, we showed that 
LDL consists of three subfractions: LDL3 with the 
highest density was most rapidly oxidized with Cu2+ 
in vitro (12). On the other hand, the LDL subfraction 
pattern is a function of plasma TG concentration. 
So, if a HRT regimen is designed with small changes 
in plasma lipids and lipoproteins, such as the pres­
ent one, then changes in LDL oxidizability will be 
minimal. This indeed could be established.
Possible explanations for the difference with our 
own findings are the different kinds of estrogens 
used (17/3-E2 versus conjugated estrogens in our 
study), the route of administration (intra-arterial, 
transdermal, implantation versus oral administra­
tion in our study), and the duration of administra­
tion (direct, 3 and 16 weeks versus 6 months in our 
study), and possibly most important the administra­
tion of a progestogen. Progestogens reportedly coun­
teract the beneficial effects of estrogen administra­
tion on lipid profiles (8),
Homocysteine is an independent risk factor for 
CVD (15). It was demonstrated that plasma homo­
cysteine concentrations in postmenopausal women 
are higher than in premenopausal women and there­
fore may contribute to the increased cardiovascular 
risk in postmenopausal women (16). Furthermore, 
postmenopausal E2/dydrogesterone administration 
for 2 years was associated with a decrease in serum
homocysteine, which may contribute to the cardio­
protective effect of HRT (17). The recently reported 
observation by Anker et al. (23) adds to this conclu­
sion. They found a reduction in plasma homocysteine 
of 29.8% after 9 to 12 months and of 24.5% after 13 
to 18 months of treatment with the anti-estrogen 
tamoxifen, a adjuvant drug that has been associated 
with reduced cardiovascular mortality, which is 
given to women with breast cancer. Our present ob­
servation during 12 months of conjugated estrogen- 
medrogestone administration, however, indicates 
that the reduction in homocysteine may only be tem­
porary. In relation to previous studies we used a 
relative high dosage of medrogestone, possibly ex­
erting an unfavorable effect on homocysteine metab­
olism. In agreement with previous observations (17), 
the decreases in homocysteine, if any, were espe­
cially observed in those women having higher homo­
cysteine concentrations, indicating that they may 
benefit the most of the homocysteine-lowering in­
fluence of HRT.
Arterioclerotic changes related to elevated homo­
cysteine concentrations have been suggested to be 
induced by increased lipid peroxidation due to reac­
tive oxygen generation by homocysteine (24). Blom 
et al. (25) failed to confirm this hypothesis in in vitro 
oxidation studies in hyperhomocysteinemic subjects. 
In the present study LDL oxidation showed a small 
but significant increase, not in line with the tempo­
rarily decreased homocysteine concentrations.
From the data obtained in this study, it can be 
concluded that this sequential HRT regimen induced 
several favorable changes in lipid and lipoprotein 
concentrations, as well as in homocysteine concen­
trations, which may counteract the minor undesir­
able changes in LDL susceptibility to oxidation. 
Therefore, our data explain in part the reduced 
risk of developing CVD in postmenopausal women 
on HRT.
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